Here are five notes:
1. The product, NanoFUSE DBM, is a novel composite allograft.
2. It received expanded 510(k) marketing clearance from the FDA for use in spinal fusion surgery.
3. Under the license agreement, Nanotherapeutics will become a minority shareholder in Amend Surgical.
4. Amend Surgical is a medical technology company focused on enhancing the bone healing/regenerative capacity of bone grafts.
5. Financial terms of the transaction were not disclosed.
More articles on devices:
US spinal surgery market outlook to 2021 — 5 things to know
NuVasive, Smith & Nephew, Medtech & more: 21 key notes
Conmed completes $265M SurgiQuest acquisition: 4 takeaways
